MedStar Health Launches Participation in Phase 3 MAGNITUDE Gene-Editing Study with First U.S. Heart...
Study examines if gene editing can help people living with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) WASHINGTON, May 2, 2024 /PRNewswire/ -- The...
prnewswire.com